Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Indication-specific Criteria
1. Immune Thrombocytopenia (ITP)
* Documented persistent or chronic primary ITP of at least 12 weeks duration from diagnosis to Cycle 1 Day 1
* History of failure or relapse to at least 2 treatment regimens for ITP
* History of exposure to a TPO-RA unless otherwise contraindicated or unavailable
* Documented history of platelets \<30 × 10\^9/L
2. Warm Autoimmune Hemolytic Anemia (wAIHA)
* Diagnosis of primary wAIHA of at least 12 weeks duration documented with a current or prior positive direct antiglobulin test (DAT) for anti-IgG (±C3d)
* Documented history of anemia with hemoglobin ≤10 g/dL
* At least one of the following: (i) haptoglobin \< lower limit of normal (LLN) (ii) indirect bilirubin \> upper limit of normal (ULN) (iii) lactate dehydrogenase\>ULN
* History of failure or relapse to at least 2 treatment regimens for wAIHA
3. Cold Agglutinin Disease (CAD)
* Diagnosis of primary CAD of at least 12 weeks duration with all of the following: (i) chronic hemolysis (ii) polyspecific DAT positive (iii) monospecific DAT strongly positive for C3d (iv) cold agglutinin titer ≥64 at 4°C (v) IgG DAT ≤1+ (vi) no overt malignant disease
* Documented history of anemia with hemoglobin ≤10 g/dL
* Evidence of hemolysis during screening: (i) indirect bilirubin
\>ULN and (ii) lactate dehydrogenase\>ULN or haptoglobin \<LLN
* History of failure or relapse to at least 1 treatment regimen for CAD
2. (All indications) If receiving protocol-specified standard-of-care medications, doses must be stable for protocol-specified durations
You may not be if
1. Secondary AIHA, CAD, or ITP
2. Treatment with any of the following within the noted period prior to study entry
1. rituximab: \<12 weeks
2. IVIg: \<4 weeks
3. sutimlimab, any use after initiation of screening is exclusionary
4. plasmapheresis, plasma exchange, or double-filtration plasmapheresis: \<8 weeks
5. transfusions with blood, blood products or other rescue medications: \<2 weeks
6. splenectomy: \<12 weeks
7. other immunomodulatory or investigational agents, except for investigational agents for COVID-19 that have been granted emergency use authorization or approved by the applicable national health authority: \<5 half-lives and requires agreement of the Medical Monitor
Clareo Health | An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)
